This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback
Trial record 3 of 4 for:    SetPoint Medical Corporation

Long Term Observational Study of a Vagal Nerve Stimulation Device in Crohn's Disease

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
SetPoint Medical Corporation Identifier:
First received: October 29, 2016
Last updated: August 2, 2017
Last verified: August 2017
This will be an open label multicenter study of the safety and efficacy of an active implantable VNS device in patients with Crohn's Disease.

Condition Intervention Phase
Crohn Disease Device: Cyberonics VNS Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Long Term Observational Study of the Safety and Efficacy of an Active Implantable Vagal Nerve Stimulation Device in Patients With Crohn's Disease

Resource links provided by NLM:

Further study details as provided by SetPoint Medical Corporation:

Primary Outcome Measures:
  • Crohn's Disease Activity Index [ Time Frame: 24 months ]

Secondary Outcome Measures:
  • Inflammatory Bowel Disease Questionnaire [ Time Frame: 24 months ]

Estimated Enrollment: 15
Study Start Date: January 2015
Estimated Study Completion Date: August 2018
Estimated Primary Completion Date: May 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cyberonics VNS
Cyberonics VNS
Device: Cyberonics VNS
Vagus nerve stimulation

Detailed Description:

Patients who complete study SPM-007 will be enrolled in this study at the time of the last visit of the preceding study. The assessments at the last visit of the preceding study will also be used as baseline measures for the current study. If the patient has previously discontinued SPM-007 and greater than 30 days have elapsed since the final visit in SPM-007, baseline measures for the current study will be repeated, and an interim medical history will be taken to assess whether any new medical conditions were diagnosed in the time between studies.

The study will continue until the last patient entered has completed 24 months in this study.

Follow-up visits will occur at 3, 6, 12, 18 and 24 months. A final follow-up visit will occur for all remaining patients at study closure when the final enrolled subject has completed 24 months on study.

An Interim Visit must be performed a maximum of 1 month after any change in device settings. Interim visits may also be performed at any time at the principal investigator's discretion; either between scheduled visits, or after the patient has completed the Month 24 Visit, if the study is still ongoing.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Patients must have enrolled in study SPM-007; including patients who either completed that study or withdrew before completion of that study.

Exclusion Criteria:

Inability to provide informed consent Significant psychiatric illness or substance abuse

All patients will be excluded who have developed any of these exclusionary conditions during the SMP-007 study, or in the interim between SPM-007 and the Day 0 of SPM-010:

  • History of unilateral or bilateral vagotomy
  • History of recurrent vaso-vagal syncope episodes
  • Known obstructive sleep apnea
  • Known history of cardiac rhythm disturbances, atrio-ventricular block of greater than first degree, or cardiac conduction pathway abnormalities other than isolated right bundle branch block or isolated left anterior fascicle block.
  • Significant pharyngeal dysfunction or swallowing difficulties
  • Clinically significant vocal cord damage or hoarseness
  • Other implanted electrically active medical devices (e.g., cardiac pacemakers, automatic implantable cardioverter-defibrillators)
  • Asthma or chronic obstructive pulmonary disease not controlled by medications, or any other disease causing clinically significant dyspnea
  • A greater than or equal to 40 pack-year smoking history
  • Active peptic ulcer disease
  • Patients with a limited life expectancy due to terminal illness
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02951650

Dubrava Hospital
Zagreb, Croatia
Humanitas Research Hospital
Milan, Italy
Academic Medical Center
Amsterdam, Netherlands
Karolinska Institute
Stockholm, Sweden
Sponsors and Collaborators
SetPoint Medical Corporation
Principal Investigator: Geert D'Haens, M.D., Ph.D. Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
  More Information

Responsible Party: SetPoint Medical Corporation Identifier: NCT02951650     History of Changes
Other Study ID Numbers: SPM-010
Study First Received: October 29, 2016
Last Updated: August 2, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by SetPoint Medical Corporation:
vagus nerve stimulation

Additional relevant MeSH terms:
Crohn Disease
Inflammatory Bowel Diseases
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases processed this record on August 18, 2017